Michael McDermott - 23 Feb 2024 Form 4 Insider Report for PFIZER INC (PFE)

Signature
Susan E. Grant, by power of atty., for Michael McDermott
Issuer symbol
PFE
Transactions as of
23 Feb 2024
Net transactions value
-$206,900
Form type
4
Filing time
27 Feb 2024, 13:47:43 UTC
Previous filing
28 Feb 2023
Next filing
28 Feb 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PFE Common Stock Options Exercise $339,344 +12,412 +15% $27.34 95,408 23 Feb 2024 Direct F1
transaction PFE Common Stock Tax liability $23,846 -859 -0.9% $27.76 94,549 23 Feb 2024 Direct F2
transaction PFE Common Stock Tax liability $274,548 -10,031 -11% $27.37 84,518 23 Feb 2024 Direct F3, F4
transaction PFE Common Stock Tax liability $83,058 -2,992 -3.5% $27.76 81,526 25 Feb 2024 Direct F5, F6
transaction PFE Common Stock Tax liability $164,792 -6,063 -7.4% $27.18 75,463 26 Feb 2024 Direct F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PFE Stock Appreciation Rights Options Exercise $0 -12,412 -100% $0.000000* 0 23 Feb 2024 Common Stock 12,412 $27.34 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
F2 The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
F3 The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
F4 Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.
F5 The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).
F6 Price is the closing price of Pfizer common stock on February 23, 2024.
F7 The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.